EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Clever Leaves Holdings Inc (CLVR) fair value: what the stock is really worth

As of Sep 29, 2026: fair value of Clever Leaves Holdings Inc $0.00, price $0.00, upside +0.0%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · Home Canada · ISIN CA1867601041

CL Clever Leaves Holdings Inc logo Thin data Sep 27, 2026

Clever Leaves Holdings Inc

CLVR · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0001 · Fairly valued (+0.0%)
!Quality 40/100
!Mixed Growth (revenue 3y +12.9 %/yr)
!Loss-making · -102.8% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (3/8)
!Narrow moat 3/100
!Evidence only low, so the estimate is less certain
!Weak on future: 27 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$576.00 $0.0001 Fair Value $0.0001 Sep 2020 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.0001 – $576.00 · the $0.0001 price screens below the $0.0001 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Clever Leaves Holdings in your weekly email

Every Wednesday you see whether Clever Leaves Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid.

Show more

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

Stock analysis

Clever Leaves Holdings Inc (CLVR) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Clever Leaves Holdings Inc reported revenue of $17.4M in FY2023 versus $7.8M in FY2019, a compound +22.1%/yr. Reported net income was −$17.9M in FY2023.

Key figures

Market cap $350 · EPS (TTM) $−4.21 · Net margin −103% · Return on equity −61.3% · Return on assets (EBIT) −35.8% · Operating margin −106% · Revenue (TTM) $17.4M · Revenue growth (YoY) +5.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 88% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 0%, CLVR screens cheaper than that median.

Fair Value models

Bear $0.0001 Fair Value $0.0001 Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0001 $0.0001 $0.0001 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.0001 $0.0001 $0.0001 54

Open the full fair value analysis →

Notify me when CLVR reaches fair value

Put CLVR on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 40/100

Of which business quality 41 · Market factors (momentum, volatility) 20

Profitability 15
Margins and returns on capital today
Quality Growth 87
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 68
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−466.4% (2019) → −89.5% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2023 is a loss year, no rate is defined from a loss
not computed

Watch CLVR, get fair value alerts →

Compare Clever Leaves Holdings Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside +0.0% · Above median
Profitability
Return on assets −23.4% · Bottom 25%
Net margin (TTM) −102.8% · Bottom 25%
Operating margin (TTM) −105.9% · Bottom 25%
Growth and dividend
Revenue growth 5.4% · Above median
Balance sheet
Debt / equity 0.03× · Below median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 14
FUTURE (revenue growth)27 · sector 24
PAST (return on equity)0 · sector 28
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.19 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Clever Leaves Holdings Inc Fair Value". https://www.fairvalue-calculator.com/stock/CLVR

Frequently asked questions

Is Clever Leaves Holdings Inc (CLVR) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% upside (fairly valued).
What is the fair value of CLVR?
Our model-based fair value for Clever Leaves Holdings Inc is $0.0001 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.0001.
What is the quality score of CLVR?
Clever Leaves Holdings Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Clever Leaves Holdings Inc (CLVR)?
Our model-based price target is the fair value of $0.0001 (as of Sep 27, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Clever Leaves Holdings Inc stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus a price of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Clever Leaves Holdings Inc (CLVR)?
Clever Leaves Holdings Inc reported trailing-twelve-month revenue of about $17.4M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Clever Leaves Holdings Inc (CLVR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Clever Leaves Holdings Inc it is $0.0001 per share (as of Sep 27, 2026), against a price of $0.0001. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Clever Leaves Holdings Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, CLVR trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLVR?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Clever Leaves Holdings Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Clever Leaves Holdings Inc worth?
The market values Clever Leaves Holdings Inc at about $350 (market capitalisation, as of Sep 27, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of Clever Leaves Holdings Inc (CLVR)?
Balance-sheet figures for Clever Leaves Holdings Inc (as of Sep 27, 2026): return on equity −61.3%, debt of 0.03 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is CLVR from its 52-week high?
Clever Leaves Holdings Inc trades at $0.0001, about 88% below its 52-week high of $0.0008 and at the low of $0.0001 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to Clever Leaves Holdings Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Clever Leaves Holdings Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLVR calculated?
We run Clever Leaves Holdings Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Clever Leaves Holdings Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Clever Leaves Holdings Inc (CLVR)?
The closing price on Sep 29, 2026 was $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Clever Leaves Holdings Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Clever Leaves Holdings Inc

How large is the market capitalisation of Clever Leaves Holdings Inc (CLVR)?
The market capitalisation of Clever Leaves Holdings Inc is $350. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Clever Leaves Holdings Inc (CLVR)?
Earnings per share at Clever Leaves Holdings Inc are $−4.21. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Clever Leaves Holdings Inc (CLVR)?
The net margin of Clever Leaves Holdings Inc is −103% (fiscal year 2023). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Clever Leaves Holdings Inc (CLVR)?
The return on equity (ROE) of Clever Leaves Holdings Inc is −61.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Clever Leaves Holdings Inc (CLVR)?
On an EBIT basis the return on assets of Clever Leaves Holdings Inc is −35.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Clever Leaves Holdings Inc (CLVR)?
The operating margin of Clever Leaves Holdings Inc is −106% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Clever Leaves Holdings Inc (CLVR)?
Revenue at Clever Leaves Holdings Inc is growing +5.4% versus a year earlier (3y avg +12.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Clever Leaves Holdings Inc (CLVR) generate?
The free cash flow of Clever Leaves Holdings Inc is −$11.5M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Clever Leaves Holdings Inc (CLVR) hold?
Clever Leaves Holdings Inc holds more cash than debt, $4.7M net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Clever Leaves Holdings Inc in the live analysis

One click puts Clever Leaves Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.